The Biologists and Clinicians Still Require Hand-Holding When it Comes to Sequence Data Analysis and Interpretation

DataAnalysis&Interpret._070616

Bioinformaticians are a bottleneck and at high demand. They are hard to find, hire, and retain, while typically being an expensive investment. This realization is not new, but has escalated with the sequence data explosion and now puts a huge challenge on commercial tool providers to build optimal analysis and interpretation solutions that will be embraced by biologists and clinicians, i.e. the non-computational scientists. Almost all commercial tool providers state that they offer a solution that is easy to use and requires minimal upfront training. However, reality shows that this is not generally holding true, and biologists/clinicians are still overwhelmed with most offerings in the field. If a solution is too “simplified,” it can’t provide the capabilities required to do a high-quality analysis on complex data. On the flip side, if the solution is too complex, it cannot be deployed and effectively used without training, which is what the field is experiencing. Furthermore, Continue reading

Merck’s Research Laboratory President Dr. Roger Perlmutter Shares His Vision on “How Personalized Medicine Will Impact Healthcare”

DNA_pill_BThe following is an interview recently conducted by the PMWC Intl. team with Dr. Roger Perlmutter (President, Merck Research Laboratories). The discussion with Dr. Perlmutter focused on various aspects of personalized medicine ranging from key promises to current and future challenges: questions  aimed at addressing how personalized medicine will influence the drug discovery process, how the pharmaceutical industry is adjusting and evolving over the next 5-10 years, what big hurdles there are to make personalized medicine a true reality, and – last but not least – how the ongoing pressure on cost control in healthcare vis-à-vis the continuing increase in drug development costs will ultimately shape the fate of personalized medicine and its acceptance by payors, providers, and patients. Continue reading

UCSC Genomics Institute’s Director David Haussler Addresses “Data Solutions in Clinical Genomics” Questions

UCSCThe following blog is a repost of a recent post by Tal Behar, Co-founder & Executive Director at PMWC Intl, on LinkedIn Pulse. We believe this post – a set of questions and answers to the UCSC Genomics Institute’s director David Haussler – is of interest to the enlightenbio audience which is why we requested the repost. It addresses big genomic data questions related to the clinical setting, such as large-scale genomics activities under way or in the process of getting started, the efforts of the Data Working Group of the Global Alliance for Genomics and Health (GA4GH) and why this working group is needed, observed challenges with data storage, analysis, and sharing platforms, and last but not least what other organizations or commercial companies can learn from organizations like the UC Santa Cruz Genomics Institute. Continue reading